신속 혈장 반응 검사 시장 규모, 점유율, 성장 분석 : 검체별, 검사 유형별, 용도별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)
Rapid Plasma Reagin Test Market Size, Share, and Growth Analysis, By Specimen (Blood, Serum), By Test Type (Traditional Tests, Rapid Tests), By Application, By End User, By Region - Industry Forecast 2025-2032
세계의 신속 혈장 반응 검사 시장 규모는 2023년에 28억 달러, 2024년 30억 9,000만 달러에서 2032년에는 67억 7,000만 달러로 성장하고, 예측 기간(2025-2032년) CAGR은 10.3%를 보일 전망입니다.
남성 동성애자, 임산부 등 고위험군의 매독 발병률 증가로 인해 신속 혈장 반응 검사에 대한 수요가 크게 증가하고 있습니다. 이러한 검사 시스템의 기술 발전은 검체 처리를 간소화하고 처리량을 향상시켜 대량 검사를 수행하는 검사실에 특히 유용합니다. 또한, 성병(STI) 검진에 초점을 맞춘 정부의 이니셔티브는 시장 성장을 더욱 촉진할 것으로 예측됩니다. 또한, 빠른 결과를 얻을 수 있는 현장 검사(POC)에 대한 선호도가 높아짐에 따라 특히 매독 및 기타 STI에 대한 인식이 높아지는 신흥 시장에서의 채택이 증가할 것으로 보입니다. 그러나 자원이 부족한 지역에서의 접근성 제한, 대체 진단법과의 경쟁, 규제적 장애물 등이 2032년 이후에도 시장 침투를 저해할 수 있습니다.
목차
서론
조사 방법
- 정보 조달
- 2차·1차 데이터 방법
- 시장 규모 예측
- 시장 전제조건과 제한
주요 요약
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porter의 Five Forces 분석
주요 시장 인사이트
- 중요 성공 요인
- 경쟁 정도
- 주요 투자 기회
- 시장 생태계
- 시장의 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
신속 혈장 반응 검사 시장 규모 : 검체별, CAGR(2025-2032년)
신속 혈장 반응 검사 시장 규모 : 검사 유형별, CAGR(2025-2032년)
신속 혈장 반응 검사 시장 규모 : 용도별, CAGR(2025-2032년)
신속 혈장 반응 검사 시장 규모 : 최종사용자별, CAGR(2025-2032년)
- 시장 개요
- 병원 및 진료소
- 진단실험실
- 연구기관
신속 혈장 반응 검사 시장 규모 : 지역별, CAGR(2025-2032년)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카
- 기타 중동 및 아프리카
경쟁 정보
- 주요 5개사 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채택한 전략
- 최근 시장 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업 개요
- 기업 상세
- 제품 포트폴리오 분석
- 기업 부문별 점유율 분석
- 매출 전년대비 비교(2022-2024년)
주요 기업 개요
- Thermo Fisher Scientific Inc.(USA)
- Danaher Corporation(USA)
- Abbott Laboratories(USA)
- F. Hoffmann-La Roche AG(Switzerland)
- Siemens Healthineers AG(Germany)
- Bio-Rad Laboratories, Inc.(USA)
- Merck KGaA(Germany)
- Quest Diagnostics(USA)
- Cardinal Health, Inc.(USA)
- bioMerieux SA(France)
- Becton, Dickinson and Company(BD)(USA)
- Sekisui Diagnostics(USA)
- Meridian Bioscience, Inc.(USA)
- Arlington Scientific Inc.(USA)
- Immunostics Inc.(USA)
- Novacyt Group(France)
- Trinity Biotech plc(Ireland)
- Atlas Medical GmbH(Germany/UK)
- Sclavo Diagnostics International S.r.l.(Italy)
결론과 제안
LSH
Global Rapid Plasma Reagin Test Market size was valued at USD 2.8 billion in 2023 and is poised to grow from USD 3.09 billion in 2024 to USD 6.77 billion by 2032, growing at a CAGR of 10.3% during the forecast period (2025-2032).
The rising incidence of syphilis, particularly among high-risk populations such as men who have sex with men and pregnant women, is significantly increasing the demand for rapid plasma reagin tests. Technological advancements in these testing systems facilitate streamlined sample processing and enhance throughput, making them particularly beneficial for high-volume laboratories. Additionally, government initiatives focused on sexually transmitted infection (STI) screening are expected to further stimulate market growth. The growing preference for point-of-care (POC) testing due to quick results will also drive adoption, especially in emerging markets where awareness of syphilis and other STIs is on the rise. However, challenges like limited access in low-resource settings, competition from alternative diagnostics, and regulatory hurdles may hinder market penetration through 2032 and beyond.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rapid Plasma Reagin Test market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Rapid Plasma Reagin Test Market Segments Analysis
Global Rapid Plasma Reagin Test Market is segmented by Specimen, Test Type, Application, End User and region. Based on Specimen, the market is segmented into Blood, Serum and Plasma. Based on Test Type, the market is segmented into Traditional Tests and Rapid Tests. Based on Application, the market is segmented into Diagnostics and Screening. Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Rapid Plasma Reagin Test Market
The Global Rapid Plasma Reagin (RPR) Test market is experiencing significant growth driven by the rising prevalence of chronic diseases and a heightened awareness of health and wellness. This surge in demand for preventive healthcare is rooted in the critical need for early syphilis detection through routine screenings, which prevents complications and limits the infection's spread. Healthcare providers are increasingly incorporating RPR testing into standard preventive care practices, particularly for high-risk populations. This proactive strategy supports overarching public health initiatives aimed at lowering sexually transmitted infection (STI) rates and encourages regular screenings to promote better health outcomes.
Restraints in the Global Rapid Plasma Reagin Test Market
The Global Rapid Plasma Reagin Test market faces obstacles due to various biological factors, including autoimmune disorders and other infections, which can trigger non-specific reactions and yield inaccurate results. This often necessitates additional confirmatory testing, potentially delaying both diagnosis and treatment. Such limitations can undermine the perceived reliability of the rapid plasma reagin test among healthcare professionals, prompting them to favor alternative diagnostic approaches. As a result, this reluctance may hinder the broader acceptance and utilization of rapid plasma reagin tests, ultimately affecting their long-term presence in the market.
Market Trends of the Global Rapid Plasma Reagin Test Market
The Global Rapid Plasma Reagin (RPR) Test market is witnessing a significant trend towards the integration of RPR testing within multiplex diagnostic platforms, streamlining STI screening processes. This innovative approach facilitates the simultaneous detection of various infections such as HIV, syphilis, and hepatitis from a single sample, thereby reducing both testing time and associated costs. Particularly beneficial in resource-limited settings, this trend enhances logistical efficiency and promotes broader RPR adoption. By embedding RPR into comprehensive diagnostic strategies, the market is not only improving STI management but also significantly expanding overall diagnostic coverage, ultimately contributing to better public health outcomes globally.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
Global Rapid Plasma Reagin Test Market Size by Specimen & CAGR (2025-2032)
- Market Overview
- Blood
- Serum
- Plasma
Global Rapid Plasma Reagin Test Market Size by Test Type & CAGR (2025-2032)
- Market Overview
- Traditional Tests
- Rapid Tests
Global Rapid Plasma Reagin Test Market Size by Application & CAGR (2025-2032)
- Market Overview
- Diagnostics
- Screening
Global Rapid Plasma Reagin Test Market Size by End User & CAGR (2025-2032)
- Market Overview
- Hospitals & Clinics
- Diagnostic Laboratories
- Research Institutes
Global Rapid Plasma Reagin Test Market Size & CAGR (2025-2032)
- North America (Specimen, Test Type, Application, End User)
- Europe (Specimen, Test Type, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Specimen, Test Type, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Specimen, Test Type, Application, End User)
- Brazil
- Rest of Latin America
- Middle East & Africa (Specimen, Test Type, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Quest Diagnostics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cardinal Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Becton, Dickinson and Company (BD) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sekisui Diagnostics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Meridian Bioscience, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Arlington Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Immunostics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novacyt Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Trinity Biotech plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Atlas Medical GmbH (Germany/UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sclavo Diagnostics International S.r.l. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
